Compare Stocks: MTSR, INSM, BNTX, and INCY

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$102.07 0.0%	$95.40	$79.52 ▼ $124.00	$25.81B	1.27	1.84 million shs	3.07 million shs
INCY Incyte	$124.37	$118.99	$81.09 ▼ $132.60	$25.21B	0.76	1.32 million shs	1.22 million shs
INSM Insmed	$118.54	$113.64	$90.39 ▼ $212.75	$25.89B	0.81	2.92 million shs	1.98 million shs
MTSR Metsera	$70.50 -0.4%	$64.53	$12.30 ▼ $83.86	$7.42B	N/A	4.84 million shs	27.90 million shs

10 Best Stocks to Own - Summer 2026

Enter your email address and we’ll send you MarketBeat’s list of ten stocks set to soar in Summer 2026, despite the threat of tariffs and what's happening in Iran. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	0.00%	-12.44%	+12.68%	+11.31%	+2.07%
INCY Incyte	0.00%	-2.69%	+4.06%	+30.11%	+46.99%
INSM Insmed	0.00%	-5.75%	+20.22%	+11.80%	-12.90%
MTSR Metsera	0.00%	0.00%	0.00%	0.00%	+99.77%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BNTX BioNTech	$102.07 0.0%	$95.40	$79.52 ▼ $124.00	$25.81B	1.27	1.84 million shs	3.07 million shs
INCY Incyte	$124.37	$118.99	$81.09 ▼ $132.60	$25.21B	0.76	1.32 million shs	1.22 million shs
INSM Insmed	$118.54	$113.64	$90.39 ▼ $212.75	$25.89B	0.81	2.92 million shs	1.98 million shs
MTSR Metsera	$70.50 -0.4%	$64.53	$12.30 ▼ $83.86	$7.42B	N/A	4.84 million shs	27.90 million shs

10 Best Stocks to Own - Summer 2026

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BNTX BioNTech	0.00%	-12.44%	+12.68%	+11.31%	+2.07%
INCY Incyte	0.00%	-2.69%	+4.06%	+30.11%	+46.99%
INSM Insmed	0.00%	-5.75%	+20.22%	+11.80%	-12.90%
MTSR Metsera	0.00%	0.00%	0.00%	0.00%	+99.77%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BNTX BioNTech	2.74	Moderate Buy	$127.81	25.22% Upside
INCY Incyte	2.56	Moderate Buy	$123.10	-1.02% Downside
INSM Insmed	3.00	Buy	$205.52	73.38% Upside
MTSR Metsera	2.00	Hold	$55.50	-21.28% Downside

Current Analyst Ratings Breakdown

Latest MTSR, INSM, BNTX, and INCY Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
8/24/2026	INCY Incyte	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong-Buy
8/20/2026	INCY Incyte	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/20/2026	INCY Incyte	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$152.00
8/20/2026	INCY Incyte	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$150.00
8/17/2026	INCY Incyte	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$110.00 ➝ $130.00
8/13/2026	INCY Incyte	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Perform	$104.00
8/10/2026	INSM Insmed	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$185.00 ➝ $195.00
8/10/2026	INSM Insmed	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/10/2026	INSM Insmed	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Overweight	$179.00 ➝ $175.00
8/7/2026	INSM Insmed	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$218.00
8/7/2026	INSM Insmed	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$170.00

(Data available from 8/31/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BNTX BioNTech	$3.25B	7.95	$1.34 per share	76.45	$96.59 per share	1.06
INCY Incyte	$5.14B	4.90	$6.18 per share	20.12	$26.32 per share	4.73
INSM Insmed	$1.14B	22.76	N/A	N/A	$3.46 per share	34.26
MTSR Metsera	N/A	N/A	N/A	N/A	$3.20 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BNTX BioNTech	-$1.29B	-$7.83	N/A	N/A	N/A	-63.54%	-6.86%	-6.00%	11/3/2026 (Estimated)
INCY Incyte	$1.29B	$7.85	15.84	15.68	3.91	27.71%	29.93%	22.88%	10/27/2026 (Estimated)
INSM Insmed	-$1.28B	-$4.11	N/A	45.42	N/A	-76.94%	-123.94%	-44.30%	10/29/2026 (Estimated)
MTSR Metsera	-$209.13M	-$6.32	N/A	N/A	N/A	N/A	-121.12%	-53.54%	N/A

Latest MTSR, INSM, BNTX, and INCY Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	INSM Insmed	-$0.6724	-$0.06	+$0.6124	-$0.06	$395.50 million	$425.49 million
8/4/2026	Q2 2026	BNTX BioNTech	-$2.3983	-$2.5340	-$0.1357	-$3.70	$180.18 million	$122.31 million
7/28/2026	Q2 2026	INCY Incyte	$2.15	$3.09	+$0.94	$2.81	$1.50 billion	$1.67 billion

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BNTX BioNTech	N/A	N/A	N/A	N/A	N/A
INCY Incyte	N/A	N/A	N/A	N/A	N/A
INSM Insmed	N/A	N/A	N/A	N/A	N/A
MTSR Metsera	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BNTX BioNTech	0.01	7.85	7.80
INCY Incyte	N/A	4.59	4.51
INSM Insmed	0.74	3.72	3.40
MTSR Metsera	N/A	4.25	5.26

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BNTX BioNTech	15.52%
INCY Incyte	96.97%
INSM Insmed	N/A
MTSR Metsera	N/A

Insider Ownership

Company	Insider Ownership
BNTX BioNTech	19.20%
INCY Incyte	16.20%
INSM Insmed	2.10%
MTSR Metsera	N/A

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BNTX BioNTech	7,807	252.88 million	204.33 million	Optionable
INCY Incyte	2,844	202.70 million	169.86 million	Optionable
INSM Insmed	1,664	218.38 million	213.80 million	Optionable
MTSR Metsera	81	105.29 million	N/A	N/A

MTSR, INSM, BNTX, and INCY Headlines

Recent News About These Companies

Railpen lifts IP Group offer with cash, Nanopore stake and Metsera upside

July 20, 2026 | proactiveinvestors.co.uk

Pfizer Reshapes Portfolio With Seagen And Metsera As COVID Winds Shift

April 8, 2026 | finance.yahoo.com

IP Group shares jump 9% as Metsera deal drives return to growth

March 17, 2026 | proactiveinvestors.co.uk

Pfizer Releases Early Obesity Data Showing Up to 12.3% Weight Loss

February 4, 2026 | finance.yahoo.com

Pfizer Bets On Monthly GLP-1 Obesity Drug To Reshape Growth Story

February 4, 2026 | finance.yahoo.com

Why Pfizer's 2026 guidance miss is 'not a major surprise'

December 16, 2025 | msn.com

Metsera (MTSR): Evaluating Valuation After Sharp Share Price Turnaround

November 14, 2025 | finance.yahoo.com

Metsera, Inc. Completes Merger and Restructures Leadership

November 14, 2025 | msn.com

Pfizer CEO Albert Bourla says aggressive bid for Metsera reflects company's 'right to win' obesity market

November 13, 2025 | aol.comA

Pfizer CEO Sees Metsera’s Drugs Hit Market As Early As 2028 After Completing Acquisition: Report

November 13, 2025 | msn.com

Metsera holders vote to approve $10B sale to Pfizer, deal closes (update)

November 13, 2025 | msn.com

Pfizer Completes Acquisition of Metsera

November 13, 2025 | businesswire.com

Metsera shareholders vote to approve $10B sale to Pfizer

November 13, 2025 | msn.com

Metsera shareholders vote for $10 billion acquisition by Pfizer

November 13, 2025 | reuters.com

Novo Nordisk Rises Despite Metsera Loss, Slashes Wegovy Price In India

November 11, 2025 | benzinga.com

What Happens After Pfizer Won $10B Bid for Metsera

November 10, 2025 | baystreet.ca

Metsera MET-097i results from two trials at ObesityWeek

November 10, 2025 | thepharmaletter.comT

Metsera stock tumbles as Novo Nordisk drops out of bidding war

November 10, 2025 | za.investing.com

Metsera (MTSR) Shares Nosedive After Pfizer Clinches Weight-Loss Biotech Deal

November 10, 2025 | finance.yahoo.com

Pfizer to acquire Metsera after winning bidding contest against Novo Nordisk

November 10, 2025 | proactiveinvestors.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTSR, INSM, BNTX, and INCY Company Descriptions

BioNTech NASDAQ:BNTX

$102.07 -0.01 (-0.01%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$102.35 +0.28 (+0.28%)

As of 04:21 AM Eastern

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer. It develops BNT122, which is in Phase II clinical trial for first-line melanoma and in Phase I clinical trial to treat multiple solid tumors; BNT131 that is in Phase I clinical trial for multiple solid tumors; BNT141 and BNT142 that are in Phase I clinical trial to treat multiple solid tumors; BNT151, BNT152, and BNT153 to treat solid tumors; BNT211 to treat multiple solid tumors, and BNT221 for pancreatic and other cancers; BNT311 which are in Phase II clinical trial to treat metastatic non-small cell lung cancer and Phase I/II clinical trial to treat multiple solid tumors; and BNT312, which is in Phase 2 clinical trial to treat multiple solid tumors, as well as ONC-392, which is in Phase III clinical trial to treat ovarian cancer and Phase I/II clinical trial to treat multiple solid tumors. It develops BNT321, an IgG1 monoclonal antibody in Phase I clinical trial for pancreatic cancer; BNT411, a small molecule immunomodulator product candidate in Phase I clinical trial for solid tumors; BNT322, which is in Phase I/Ib clinical trial for multiple solid tumors; and prophylactic vaccine for shingles, malaria, tuberculosis, HSV-2, and other infectious diseases. It has collaborations with Genentech, Inc.; Sanofi S.A.; Genmab A/S; Pfizer Inc.; Shanghai Fosun Pharmaceutical (Group) Co., Ltd; and Ryvu Therapeutics S.A. BioNTech SE was incorporated in 2008 and is based in Mainz, Germany.

Incyte NASDAQ:INCY

$124.37 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$124.50 +0.13 (+0.10%)

As of 04:01 AM Eastern

Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics for hematology/oncology, and inflammation and autoimmunity areas in the United States and internationally. The company offers JAKAFI (ruxolitinib) for treatment of intermediate or high-risk myelofibrosis, polycythemia vera, and steroid-refractory acute graft-versus-host disease; MONJUVI (tafasitamab-cxix)/MINJUVI (tafasitamab) for relapsed or refractory diffuse large B-cell lymphoma; PEMAZYRE (pemigatinib), a fibroblast growth factor receptor kinase inhibitor that act as oncogenic drivers in liquid and solid tumor types; ICLUSIG (ponatinib) to treat chronic myeloid leukemia and Philadelphia-chromosome positive acute lymphoblastic leukemia; and ZYNYZ (retifanlimab-dlwr) to treat adults with metastatic or recurrent locally advanced Merkel cell carcinoma, as well as OPZELURA cream for treatment of atopic dermatitis. Its clinical stage products include retifanlimab under Phase 3 clinical trials for squamous cell carcinoma of the anal canal and non-small cell lung cancer; axatilimab, an anti-CSF-1R monoclonal antibody under Phase 2 that is being developed as a therapy for patients with chronic GVHD; INCA033989 to inhibit oncogenesis; INCB160058, which is being developed as a disease-modifying therapeutic; and INCB99280 and INCB99318 for the treatment solid tumors. The company also develops INCB123667, INCA32459, and INCA33890, as well as Ruxolitinib cream, Povorcitinib, and INCA034460. It has collaboration out-license agreements with Novartis and Lilly; in-license agreements with Agenus, Merus, MacroGenics, and Syndax; and collaboration and license agreement with China Medical System Holdings Limited for the development and commercialization of povorcitinib. The company sells its products to specialty, retail, and hospital pharmacies, distributors, and wholesalers. The company was formerly known as Incyte Genomics Inc and changed its name to Incyte Corporation in March 2003. Incyte Corporation was incorporated in 1991 and is headquartered in Wilmington, Delaware.

Insmed NASDAQ:INSM

$118.54 0.00 (0.00%)

Closing price 08/28/2026 04:00 PM Eastern

Extended Trading

$121.08 +2.54 (+2.14%)

As of 04:13 AM Eastern

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Insmed's earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension.

Metsera NASDAQ:MTSR

Metsera, Inc. is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o. The company was founded by Clive A. Meanwell in 2022 and is headquartered in New York.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MTSR, INSM, BNTX, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MTSR, INSM, BNTX, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MTSR, INSM, BNTX, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTSR, INSM, BNTX, and INCY Company Descriptions

BioNTech NASDAQ:BNTX

Incyte NASDAQ:INCY

Insmed NASDAQ:INSM

Metsera NASDAQ:MTSR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest MTSR, INSM, BNTX, and INCY Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest MTSR, INSM, BNTX, and INCY Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

MTSR, INSM, BNTX, and INCY Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

MTSR, INSM, BNTX, and INCY Company Descriptions

BioNTech NASDAQ:BNTX

Incyte NASDAQ:INCY

Insmed NASDAQ:INSM

Metsera NASDAQ:MTSR

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools